Anemia in HIV infection: Clinical impact and evidence-based management strategies

Clinical Infectious Diseases

Volumn 38, Issue 10, 2004, Pages 1454-1463

  Volberding, Paul A ^a,g   Levine, Alexandra M ^b   Dieterich, Douglas ^d   Mildvan, Donna ^e   Mitsuyasu, Ronald ^c   Saag, Michael ^f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; ANTIPROTOZOAL AGENT; ANTIRETROVIRUS AGENT; CIDOFOVIR; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DOXORUBICIN; FLUCYTOSINE; FOSCARNET; GANCICLOVIR; INTERFERON; METHOTREXATE; PACLITAXEL; PEGINTERFERON; PENTAMIDINE; PYRIMETHAMINE; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN; SULFONAMIDE; TRIMETHOPRIM; VINBLASTINE; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANEMIA; BONE MARROW SUPPRESSION; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DISEASE COURSE; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; FATIGUE; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTIOUS HEPATITIS; NONHUMAN; OPTIMAL DRUG DOSE; PATIENT CARE; PHYSICAL CAPACITY; PHYSICIAN; PNEUMOCYSTIS CARINII; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK FACTOR; SURVIVAL RATE;

ANEMIA; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; EPOETIN ALFA; FORECASTING; HEPATITIS C; HIV INFECTIONS; HUMANS; QUALITY OF LIFE;

EID: 2442711324     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/383031     Document Type: Review

References (57)

1. Sipsas NV, Kokori SI, Ioannidis JPA, Kyriaki D, Tzioufas AG, Kordossis T. Circulating autoantibodies to erythropoietin are associated with human immunodeficiency virus type 1-related anemia. J Infect Dis 1999; 180:2044-7.
2. Hambleton J. Hematologic complications of HIV infection. Oncology 1996; 10:671-80.
3. Levine AM. Anemia, neutropenia, and thrombocytopenia: pathogenesis and evolving treatment options in HIV-infected patients. Medscape HIV Clinical Management Series. 1999; 10:1-27. Available at: http: //www.medscape.com/ medscape/HIV/ClinicalMgmt/CM.v10/public/ index-CM.v10.html. Accessed on 29 September 2002.
4. Spivak JL, Barnes DC, Fuchs E, Quinn TC. Serum immunoreactive erythropoietin in HIV-infected patients. JAMA 1989; 261:3104-7.
5. Dobs AS. Androgen therapy in AIDS wasting. Baillieres Clin Endocrinol Metab 1998; 12:379-90.
6. Coyle TE. Hematologic complications of human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Med Clin North Am 1997; 81:449-70.
7. McGinniss MH, Macher AM, Rook AH, Alter HJ. Red cell autoantibodies in patients with acquired immune deficiency syndrome. Transfusion 1986; 26:405-9.
8. Rule S, Reed C, Costello C. Fatal haemophagocytic syndromes in HIV-antibody positive patient. Br J Haematol 1991; 79:127.
9. Blanche P, Robert F, Dupouy-Camet J, Sicard D. Toxoplasmosis-associated hemophagocytic syndrome in a patient with AIDS: diagnosis by the polymerase chain reaction. Clin Infect Dis 1994; 19:989-90.
10. Sasadeusz J, Buchanan M, Speed B. Reactive haemophagocytic syndrome in human immunodeficiency virus infection. J Infect 1990; 20:65-8.
11. Rarick MU, Espina B, Mocharnuk R, Trilling Y, Levine AM. Thrombotic thrombocytopenic purpura in patients with human immunodeficiency virus infection: a report of three cases and review of the literature. Am J Hematol 1992; 40:103-9.
12. Soriano V, Sulkowski M, Bergin C, et al. Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS 2002; 16:813-28.
13. 12 malabsorption in patients with acquired immunodeficiency syndrome. Arch Intern Med 1989; 149:2039-41.
14. Maddrey WC. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients. Semin Liver Dis 1999; 19(Suppl 1):67-75.
15. Levine AM, Berhane K, Masri-Lavine L, et al. Prevalence and correlates of anemia in a large cohort of HIV infected women: Women's Interagency HIV Study. J Acquir Immune Defic Syndr 2001; 26:28-35.
16. Creagh T, Mildvan D. Greater prevalence of anemia in women and African Americans with HIV/AIDS in the HAART era: a study of 10,000 patients [abstract 475]. The Anemia Prevalence Study Group. In: Program and abstracts of the 40th Annual Meeting of the Infectious Diseases Society of America (Chicago). Alexandria, VA: Infectious Diseaes Society of America, 2002:127.
17. Sullivan PS, Hanson DL, Chu SY, Jones JL, Ward JW. Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: results from the Multistate Adult and Adolescent Spectrum of HIV Disease Surveillance Project. The Adult/Adolescent Spectrum of Disease Group. Blood. 1998; 91:301-8.
18. Sharp V, Paredes J, Steinbock C. Anemia in HIV disease in the HAART era: is it common? [abstract 3179]. Blood 1999; 94(Suppl I):8b.
19. Semba RD, Shah N, Klein RS, et al. Prevalence and cumulative incidence of and risk factors for anemia in a multicenter cohort study of human immunodeficiency virus-infected and -uninfected women. Clin Infect Dis 2002; 34:260-6.
20. Mocroft A, Kirk O, Barton SE, et al, Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA Study Group. AIDS 1999; 13:943-50.
21. Fischl M, Galpin JE, Levine JD, et al. Recombinant human erythropoietin for patients with AIDS treated with zidovudine. N Engl J Med 1990; 322:1488-93.
22. Henry DH, Beall GN, Benson CA, et al. Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy. Ann Intern Med 1992; 117:739-48.
23. Semba RD. Iron-deficiency anemia and the cycle of poverty among human immunodeficiency virus-infected women in the inner city. Clin Infect Dis 2003; 37(Suppl 2):S105-11.
24. Walker RE, Parker RI, Kovacs JA, et al. Anemia and erythropoiesis in patients with the acquired immunodeficiency syndrome (AIDS) and Kaposi sarcoma treated with zidovudine. Ann Intern Med 1988; 108:372-6.
25. Richman DD, Fischl MA, Grieco MH, et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS related complex: a double-blind, placebo controlled trial. New Engl J Med 1987; 317:192-7.
26. Gill PS, Rarick MU, Brynes RK, Causey D, Levine AM. Azidothymidine and bone marrow failure in AIDS. Ann Intern Med 1987; 107:502-5.
27. Dainak N, Worthington M, Riordan MA, et al. 3-Azido-3deoxythymidine (AZT) inhibits proliferation in vitro of human haematopoietic progenitor cells. Br J Haematol 1988; 69:299-304.
28. Falguera M, Perez-Mur J, Puig T, Cao G. Study of the role of vitamin B12 and folinic acid supplementation in preventing hematologic toxicity of zidovudine. Eur J Haematol 1995; 55:97-102.
29. Lundgren JD, Mocroft A, Gatell JM, et al. A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: results from the EuroSIDA Study. J Infect Dis 2002; 185:178-87.
30. Lewden C, Leport C, Cuzin L, et al. Prognostic factors of mortality in the APROCO-ANRS EP11 cohort of HIV-1 infected adults started on a protease inhibitor-containing therapy [abstract 1909]. In: Program and abstracts of the 40th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto, Ontario). Washington, DC: American Society for Microbiology, 2000:341.
31. Breitbart W, McDonald MV, Rosenfeld B, Monkman ND, Passik S. Fatigue in ambulatory AIDS patients. J Pain Symptom Manage 1998; 15:159-67.
32. Groopman JE. Fatigue in cancer and HIV/AIDS. Oncology 1998; 12:335-44.
33. Barroso J. A review of fatigue in people with HIV infection. J Assoc Nurses AIDS Care 1999; 10:42-9.
34. Darko DF, McCutchan JA, Kripke DF, Gillin JC, Golshan S. Fatigue, sleep disturbance, disability, and indices of progression of HIV infection. Am J Psychiatry 1992; 149:514-20.
35. Bucciardi R, Goodall RL, Fragola V, et al. Quality of life at randomisation in patients enrolled in the INITIO trial [abstract P57]. In: Program and abstracts of the 6th International Congress on Drug Therapy in HIV Infection. (Glasgow). The Gardiner Caldwell Group, 2002:34.
36. Abrams DI, Steinhart C, Frascino R. Epoetin alfa therapy for anaemia in HIV-infected patients: impact on quality of life. Int J STD AIDS 2000; 11:659-65.
37. + patients [poster ThPeB7381] In: Proceedings of the XIV International AIDS Conference (Barcelona). Stockholm: International AIDS Society, 2002.
38. Saag MS, Levine AM, Leitz GJ, Bowers PJ. Once-weekly epoetin alfa increases hemoglobin and improves quality of life in anemic HIV+ patients [poster] In: Proceedings of the 39th Annual Meeting of the Infectious Diseases Society of America (San Francisco). Alexandria, VA: Infectious Diseases Society of America, 2001.
39. Moore RD, Forney D. Anemia in HIV-infected patients receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 29:54-7.
40. Semba RD, Shah N, Klein RS, et al. Highly active antiretroviral therapy associated with improved anemia among HIV-infected women. AIDS Patient Care STDs 2001; 15:473-80.
41. Semba RD, Shah N, Vlahov D. Improvement of anemia among HIV-infected injection drug users receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 26:315-9.
42. Servais J, Nkoghe D, Schmit J-C, et al. HIV-associated hematologic disorders are correlated with plasma viral load and improve under highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 28:221-5.
43. Moore RD, Keruly JC, Chaisson RE. Anemia and survival in HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 19:29-33.
44. Levine A, Berhane K, Sanchez MN, et al. Relationship between highly active anti-retroviral therapy (HAART), anemia and survival in a large cohort of HIV infected women (Women's Interagency HIV Study-WIHS) [abstract MoPeB2180]. In: Program and abstracts of the 13th International AIDS Conference (Durban, South Africa). Stockholm: International AIDS Society, 2000.
45. Levine AM, Berhane K, Masri-Lavine L, et al. Impact of anemia on the survival of HIV infected women [abstract 2091]. Blood 2001; 98:501a.
46. Ferri RS, Adinolfi A, Orai AJ, et al. Treatment of anemia in patients with HIV infection - part 2: guidelines for management of anemia. J Assoc Nurses AIDS Care 2002; 13:50-9.
47. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon alfa-2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration ribavirin dose. Ann Intern Med 2004; 140:346-55.
48. Dieterich DT, Weisz KB, Goldman DJ, Malicdem ML. Combination treatment with interferon (IFN) and ribavirin (RBV) for hepatitis C (HCV) in HIV-coinfected patients [abstract]. Hepatology 1999; 30:422A.
49. Wasserman R, Brau N, Hassanein TI, Bini E, Sulkowski M, Dieterich D. Once weekly epoetin alfa increases hemoglobin and decreases RBV discontinuation among HCV patients who develop anemia on RBV/INF therapy: AASLD report on HCV therapy toxicities [abstract 833]. In: Programs and abstracts of the 51st Annual Meeting of the American Association for the Study of Liver Diseases (Dallas). 2000:368A.
50. Sulkowski M, Wasserman R, Brau N, Hassanein T, Bini E, Dieterich D. Once-weekly recombinant human erythropoietin (epoetin alfa) facilitates optimal ribavirin (RBV) dosing in hepatitis C virus-infected patients receiving interferon-α-2b (IFN)/RBV therapy [poster 18]. In: Program and abstracts of the Hepatitis Single-Topic Conference (Chicago). 2001.
51. Dieterich DT, Pockros PJ, Schiff ER, et al. Epoetin alfa (Procrit®) once weekly maintains ribavirin dose in hepatitis C virus (HCV)-infected patients treated with combination therapy: interim results of a randomized, double-blind, placebo-controlled study [abstract 493]. Hepatology 2002; 36.
52. Afdahl NH, Dieterich DT, Pockros PJ, et al. Epoetin alfa treatment of anemic HCV-infected patients allows for maintenance of ribavirin dose, increases hemoglobin levels, and improves quality of life versus placebo: a randomized, double-blind, multicenter study [abstract 505]. Gastroenterology 2003; 124(4 Suppl 1):A-714.
53. L through Stat5 in erythropoietin-dependent progenitor cell lines. J Biol Chem 1999; 274:22165-9.
54. L expression. Blood 1999; 94:87-96.
55. Brines ML, Ghezzi P, Keenan S, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 2000; 97:10526-31.
56. Ehrenreich H, Hasselblatt M, Dembowski C, et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002; 8:495-505.
57. Volberding P. Consensus statement: anemia in HIV infection - current trends, treatment options, and practice strategies. The Anemia in HIV Working Group. Clin Ther 2000; 22:1004-20.